Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension ...(atrics Section onCardiology and Cardiac ...)

Date:6/23/2008

atrics Section on Cardiology and Cardiac Surgery; of the American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiopulmonary, Perioperative and Critical Care; of the American College of Chest Physician; and of the American College of Cardiology. She is immediate past Chairman of the American Heart Association (AHA) Council on Cardiovascular Disease in the Young. In addition, she is a member of the European Society of Cardiology Task Force for Primary Pulmonary Hypertension and a consultant to the National Heart, Lung and Blood Institute (NHLBI) Division of Lung Diseases and Office of Rare Diseases. Among her editorial responsibilities, Dr. Barst is a board member of Circulation and an abstract reviewer for Annual Scientific Sessions of the AHA and American Thoracic Society. Professional accolades include the Scleroderma Foundation Research, Education, and Support Award; the Clinician-Scientist Award, AHA; and the Clinical Investigator Award, NHLBI.

About the Pulmonary Hypertension Association

The Pulmonary Hypertension Association (PHA) is dedicated to finding ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness. The vision of PHA is to improve the lives of those affected by pulmonary hypertension.

More information about PHA is available at http://www.phassociation.org.

About Actelion Pharmaceuticals

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, C
'/>"/>

SOURCE Pulmonary Hypertension Association; Actelion Ltd Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
2. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
4. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
7. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
8. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
9. Presentation of Phase IIa Results for Cytos Biotechnologys Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
10. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
11. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer